| BINV Stock | | | SEK 31.65 0.10 0.32% |
CEO
Dr. Martin Welschof, Ph.D. was appointed President and Chief Executive Officer of BioInvent International Aktiebolag effective as of September 1, 2018. He holds Ph.D. in recombinant antibody technology. He did postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech and CEO of Opsona Therapeutics, Dublin, Ireland. since 2018.
| Age | 62 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 46 4 62 86 85 50 |
| Web | https://www.bioinvent.com |
BioInvent International Management Efficiency
The company has return on total asset
(ROA) of
(0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.0274) %, meaning that it generated substantial loss on money invested by shareholders. BioInvent International's management efficiency ratios could be used to measure how well BioInvent International manages its routine affairs as well as how well it operates its assets and liabilities.
BioInvent International AB has accumulated 21.53
M in total debt with debt to equity ratio
(D/E) of 22.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioInvent International has a current ratio of 2.68, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BioInvent International until it has trouble settling it off, either with new capital or with free cash flow. So, BioInvent International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioInvent International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioInvent to invest in growth at high rates of return. When we think about BioInvent International's use of debt, we should always consider it together with cash and equity.
Similar Executives
BioInvent International AB focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, and internationally. The Company was founded in 1997 and is based in Lund, Sweden. BioInvent International operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 68 people. BioInvent International AB (BINV) is traded on Stockholm Exchange in Sweden and employs 93 people.
Management Performance
BioInvent International Leadership Team
Elected by the shareholders, the BioInvent International's board of directors comprises two types of representatives: BioInvent International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioInvent. The board's role is to monitor BioInvent International's management team and ensure that shareholders' interests are well served. BioInvent International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioInvent International's outside directors are responsible for providing unbiased perspectives on the board's policies.
BioInvent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioInvent International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for BioInvent Stock Analysis
When running BioInvent International's price analysis, check to
measure BioInvent International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioInvent International is operating at the current time. Most of BioInvent International's value examination focuses on studying past and present price action to
predict the probability of BioInvent International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioInvent International's price. Additionally, you may evaluate how the addition of BioInvent International to your portfolios can decrease your overall portfolio volatility.